| Assessment Status | Rapid Review Complete |
| HTA ID | 19038 |
| Drug | Alutard SQ® honey bee and Alutard SQ® wasp venoms |
| Brand | Alutard SQ® |
| Indication | As allergy immunotherapies for patients with a documented history of generalised and/or systemic IgE-mediated allergic reactions due to sensitisation to honey bee venom (Apis mellifera) and wasp venom (Vespula spp.), respectively. |
| Assessment Process | |
| Rapid review commissioned | 04/02/2020 |
| Rapid review completed | 10/03/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Alutard SQ® honey bee venom and Alutard SQ® wasp venom be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013. |
The HSE has approved reimbursement, July 2020.
